Cure8 research brief
Knowing which patients are more likely to stay on vedolizumab over time can help patients and clinicians set expectations and consider alternative strategies earlier (for example, in people with Crohn’s disease and perianal disease or older adults with UC).
Adults with ulcerative colitis or Crohn’s disease considering or currently on vedolizumab; clinicians managing biologic treatment choices; researchers studying treatment persistence.
This study reports real-world, retrospective data from 107 patients (64 UC, 43 CD) treated with vedolizumab (VDZ). Median observed treatment duration was 507 days for UC and 266 days for CD. One-year persistence was about 69% for UC and 48% for CD; two-year persistence fell to ~60% (UC) and ~32% (CD).
In ulcerative colitis, older age was associated with lower VDZ persistence in adjusted analysis. In Crohn’s disease, presence of perianal disease was an independent predictor of lower VDZ persistence (HR 2.54).
These findings are from the article abstract (structured-content depth: abstract) and summarize the reported associations; they do not provide treatment recommendations or individual prognoses.
This is a retrospective, single-cohort real-world study reported in the article abstract. It identifies associations (predictors) with treatment persistence but does not establish causation. Details such as the patient population, disease severity, and concomitant treatments are summarized in the abstract; consult the full paper for complete methods and limitations.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
If validated in clinical studies, extending the interval between subcutaneous vedolizumab doses could reduce injection frequency, costs, and treatment burden for some patients on maintenance therapy.
